Potent and selective antagonist for the human type I interleukin-1 (IL-1) receptor (IC50
values are 8 nM, > 6.7 mM and > 200 mM for human type I, human type II and murine type I IL-1 receptors respectively). Blocks IL-1-induced expression of ICAM-1 and E-selectin in HUVECs and IL-1β
induction of IL-8 in human dermal fibroblasts. Reduces IL-1β
-induced IL-6 production and exhibits anti-inflammatory activity in vivo
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Low level laser therapy (LLLT) decreases pulmonary microvascular leakage, neutrophil influx and IL-1β levels in airway and lung from rat subjected to LPS-induced inflammation.
Aimbire et al.
AF12198, a novel low molecular weight antagonist, selectively binds the human type I interleukin (IL)-1 receptor and blocks in vivo responses to IL-1.
Akeson et al.
The citations listed below are publications that use Tocris products. Selected citations for AF 12198 include:
Showing Results 1 - 1 of 1